WASHINGTON, May 23 (Reuters) - Helicos BioSciences Corp., a genetic analysis technologies firm, on Wednesday cut the expected price of its planned initial public offering to a range of $10 to $11 per share from a previous estimate of $13 to $15.
WASHINGTON, May 23 (Reuters) - Helicos BioSciences Corp., a genetic analysis technologies firm, on Wednesday cut the expected price of its planned initial public offering to a range of $10 to $11 per share from a previous estimate of $13 to $15.
